Transition of care is a frequently requested topic in the Duchenne and rare disease community as it pertains to planning, setting up personnel, location of resources, and much more. Please join us on July 9 to hear from Dr. Aaron Zelikovich and Dr. Dennis Keselman on transition of care and planning for adult care.
Community Webinar: Transition of Care
July 9, 2026 | 1PM ET
Dr. Aaron Zelikovich is a neuromuscular-trained neurologist practicing at Northwell Health in New York City. He completed his medical school at Indiana University, neurology residency at Weill Cornell, and neuromuscular medicine fellowship at the University of Pennsylvania. He is the director of the adult multi-disciplinary MDA clinic at Lenox Hill Hospital and is passionate about improving medical care for adults with DMD. He has been working with patients with DMD since 2013 in various roles, including research coordinator, volunteer, trainee, and now as a practicing neurologist. His research is focused on improving multidisciplinary care in adults, transitioning from pediatric to adult clinics, and the effects of steroids in adults with DMD.
Dr. Dennis Keselman is a pediatric neuromuscular neurologist with Boston Children’s Health Physicians of NY & CT and Westchester Medical Center, both in Westchester County, NY. He completed his undergraduate training at New York University, earned his medical degree from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and went on to complete Child Neurology residency followed by fellowship training in Pediatric Neuromuscular Medicine with additional specialization in gene therapy at the Children’s Hospital of Philadelphia. He serves as Medical Director of the Pediatric Neuromuscular Medicine Program and Co-Medical Director of the Muscular Dystrophy Association Care Center at Westchester Medical Center. Dr. Keselman cares for children with a wide range of neuromuscular conditions, and has particular interest and expertise in advanced neuromuscular diagnostics and emerging molecular therapies. His academic interests focus on improving access to novel treatments and understanding outcomes for children receiving gene-based therapies, and he is actively involved in clinical research and education.
